LPDX: LipoScience Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 22, 12:40 PM LipoScience (LPDX +3.4%) trades up today after announcing the availability of its NMR lipoprotein particle testing using the Vantera Clinical Analyzer through Mayo Medical Laboratories. The analysis provides physicians and patients with a detailed assessment of cardiovascular disease risk from a single blood test that measures the concentration of low-density lipoprotein particles and other lipoprotein information. Comment! [Healthcare, On the Move]
Friday, May 10, 12:52 PM Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%. Comment! [On the Move]
Friday, May 10, 12:34 PM LipoScience (LPDX -22.8%) tanks after CEO Richard Brajer expresses his dissatisfaction with the company's revenue performance in Q1 (-1.2% Y/Y). LipoProfile test order growth fell to 8.7% Y/Y versus Y/Y growth of 14.8% in Q4, although orders did rise Q/Q. The main problems — which include difficulties ramping up new sales reps, faster direct business-to-lab partner conversion, and managed care headwinds — "cannot be fixed overnight," Brajer laments. In light of this, LPDX lowers its FY13 revenue guidance to $54-56M (consensus is $61.43M). (PR) Comment! [Healthcare, On the Move]
Friday, May 10, 6:18 AM LipoScience (LPDX): Q1 EPS of -$0.19 misses by $0.01. Revenue of $13.6M misses by $0.55M. (PR) Comment! [Earnings, Breaking News]
Wednesday, March 27, 4:31 PM LipoScience (LPDX): Q4 EPS of $0.13. Revenue of $13.6M (+8.6% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 19, 1:51 PM LipoScience (LPDX +0.6%) moves up after Piper Jaffray initiates the shares with an Overweight and a $15.00 price target. Piper notes that ongoing traction converting its LDL-C patient monitoring assays to LDL-P and represents a potential $330M annual revenue run-rate, which would exceed both its top and bottom-line projections. Separately, Barclay's and UBS also initiated coverage with an Overweight and Buy, respectively. Comment! [Healthcare, On the Move]
Friday, January 25, 10:37 AM IPO LipoScience (LPDX) opens for trading this morning at $9.75 per share after pricing 5M shares at $9, the low end of its previously reduced $9 - $10 range. Comment! [Healthcare]
Friday, January 25, 8:43 AM LipoScience (LPDX) cuts its IPO range to $9-10 from $13-15. At 5M shares, that will be about $48M raised for the medical diagnostic firm whose nuclear magnetic resonance (NMR) LipoProfile test provides risk assessment for cardiovascular events. Comment! [Healthcare]

LPDX LipoScience

LPDX

LipoScience